SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma

Elisabet Ampudia-Mesias; Samia El-Hadad; Charles Scott Cameron; Adelheid Wöhrer; Thomas Ströbel; Nurten Saydam; Okay Saydam

doi:10.3390/cancers14081984

SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma

Elisabet Ampudia-Mesias, Samia El-Hadad, Charles Scott Cameron, Adelheid Wöhrer, Thomas Ströbel, Nurten Saydam, Okay Saydam

Pediatrics - Hematology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Extracellular vesicles (EVs) may be used as a non-invasive screening platform to discover markers associated with early diagnosis, prognosis, and treatment response. Such an approach is invaluable for diseases such as glioblastoma, for which only a few non-invasive diagnostic or prognostic markers are available. We used mass spectrometry to analyze proteomics profiles of EVs derived from four glioblastoma cell lines and human primary astrocytes (HPAs) and found that SRPX is the only protein enriched in the majority of glioblastoma EVs that was absent in the HPA-derived EVs. Then, we evaluated the relationship between SRPX protein expression and tumor grade using immunohistochemical staining (IHC) and performed colony formation and viability assays to analyze the possible function of SRPX in glioblastoma. SRPX mRNA and protein expression were associated with tumor grade. Moreover, temozolomide (TMZ)-resistant tumor tissues showed highly positive SRPX staining, compared to all other tumor grades. Additionally, glioblastoma cells displayed enhanced SRPX gene expression when exposed to TMZ. Knockdown of SRPX gene expression via siRNA inhibited cell viability. Taken together, the results of this study suggest that SRPX can be used as a novel tumor marker for diagnostic and prognostic purposes and can also be a therapeutic target for glioblastomas.

Original language	English (US)
Article number	1984
Journal	Cancers
Volume	14
Issue number	8
DOIs	https://doi.org/10.3390/cancers14081984
State	Published - Apr 1 2022

Bibliographical note

Funding Information:
Acknowledgments: This work was supported, in part, by UMN, Medical School Start-Up (OS). This work was supported by the resources and staff at the University of Minnesota University Imaging Centers (UIC). SCR_020997.

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

EVs
SRPX
glioblastoma
proteomics

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3390/cancers14081984

OpenUrl availability

Full text

Cite this

@article{9e9b26243aad4d65b96fa9e2c70d9a1e,

title = "SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma",

abstract = "Extracellular vesicles (EVs) may be used as a non-invasive screening platform to discover markers associated with early diagnosis, prognosis, and treatment response. Such an approach is invaluable for diseases such as glioblastoma, for which only a few non-invasive diagnostic or prognostic markers are available. We used mass spectrometry to analyze proteomics profiles of EVs derived from four glioblastoma cell lines and human primary astrocytes (HPAs) and found that SRPX is the only protein enriched in the majority of glioblastoma EVs that was absent in the HPA-derived EVs. Then, we evaluated the relationship between SRPX protein expression and tumor grade using immunohistochemical staining (IHC) and performed colony formation and viability assays to analyze the possible function of SRPX in glioblastoma. SRPX mRNA and protein expression were associated with tumor grade. Moreover, temozolomide (TMZ)-resistant tumor tissues showed highly positive SRPX staining, compared to all other tumor grades. Additionally, glioblastoma cells displayed enhanced SRPX gene expression when exposed to TMZ. Knockdown of SRPX gene expression via siRNA inhibited cell viability. Taken together, the results of this study suggest that SRPX can be used as a novel tumor marker for diagnostic and prognostic purposes and can also be a therapeutic target for glioblastomas.",

keywords = "EVs, SRPX, glioblastoma, proteomics",

author = "Elisabet Ampudia-Mesias and Samia El-Hadad and Cameron, {Charles Scott} and Adelheid W{\"o}hrer and Thomas Str{\"o}bel and Nurten Saydam and Okay Saydam",

note = "Funding Information: Acknowledgments: This work was supported, in part, by UMN, Medical School Start-Up (OS). This work was supported by the resources and staff at the University of Minnesota University Imaging Centers (UIC). SCR_020997. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = apr,

day = "1",

doi = "10.3390/cancers14081984",

language = "English (US)",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

TY - JOUR

T1 - SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma

AU - Ampudia-Mesias, Elisabet

AU - El-Hadad, Samia

AU - Cameron, Charles Scott

AU - Wöhrer, Adelheid

AU - Ströbel, Thomas

AU - Saydam, Nurten

AU - Saydam, Okay

N1 - Funding Information: Acknowledgments: This work was supported, in part, by UMN, Medical School Start-Up (OS). This work was supported by the resources and staff at the University of Minnesota University Imaging Centers (UIC). SCR_020997. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Extracellular vesicles (EVs) may be used as a non-invasive screening platform to discover markers associated with early diagnosis, prognosis, and treatment response. Such an approach is invaluable for diseases such as glioblastoma, for which only a few non-invasive diagnostic or prognostic markers are available. We used mass spectrometry to analyze proteomics profiles of EVs derived from four glioblastoma cell lines and human primary astrocytes (HPAs) and found that SRPX is the only protein enriched in the majority of glioblastoma EVs that was absent in the HPA-derived EVs. Then, we evaluated the relationship between SRPX protein expression and tumor grade using immunohistochemical staining (IHC) and performed colony formation and viability assays to analyze the possible function of SRPX in glioblastoma. SRPX mRNA and protein expression were associated with tumor grade. Moreover, temozolomide (TMZ)-resistant tumor tissues showed highly positive SRPX staining, compared to all other tumor grades. Additionally, glioblastoma cells displayed enhanced SRPX gene expression when exposed to TMZ. Knockdown of SRPX gene expression via siRNA inhibited cell viability. Taken together, the results of this study suggest that SRPX can be used as a novel tumor marker for diagnostic and prognostic purposes and can also be a therapeutic target for glioblastomas.

AB - Extracellular vesicles (EVs) may be used as a non-invasive screening platform to discover markers associated with early diagnosis, prognosis, and treatment response. Such an approach is invaluable for diseases such as glioblastoma, for which only a few non-invasive diagnostic or prognostic markers are available. We used mass spectrometry to analyze proteomics profiles of EVs derived from four glioblastoma cell lines and human primary astrocytes (HPAs) and found that SRPX is the only protein enriched in the majority of glioblastoma EVs that was absent in the HPA-derived EVs. Then, we evaluated the relationship between SRPX protein expression and tumor grade using immunohistochemical staining (IHC) and performed colony formation and viability assays to analyze the possible function of SRPX in glioblastoma. SRPX mRNA and protein expression were associated with tumor grade. Moreover, temozolomide (TMZ)-resistant tumor tissues showed highly positive SRPX staining, compared to all other tumor grades. Additionally, glioblastoma cells displayed enhanced SRPX gene expression when exposed to TMZ. Knockdown of SRPX gene expression via siRNA inhibited cell viability. Taken together, the results of this study suggest that SRPX can be used as a novel tumor marker for diagnostic and prognostic purposes and can also be a therapeutic target for glioblastomas.

KW - EVs

KW - SRPX

KW - glioblastoma

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=85128179782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128179782&partnerID=8YFLogxK

U2 - 10.3390/cancers14081984

DO - 10.3390/cancers14081984

M3 - Article

C2 - 35454889

AN - SCOPUS:85128179782

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 8

M1 - 1984

ER -

SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this